Navigation Links
Generic in Medical Technology

VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful

... of people who had switched from a brand-name to a generic AED, while side effects increased for 49 percent ... for 15 percent of those who had switched from a generic to brand AED, while side effects increased for 18 ... problems after switching between different generic formulations of an AED. "Brand names of ...

Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms

... April 27 /PRNewswire-USNewswire/ -- Men taking generic drugs may be more likely to have less effective ... Urological Association (AUA) showing that generic substitutes for alpha blockers and 5-alpha ... with an average age of 64, who were switched to generic alternatives by their primary care physician or ...

ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance

... (FDA) of comments on FDA's Office of generic Drugs' (OGD) December 2008 draft guidance to establish the bioequivalence (BE) of generic copies of Vancocin(R) (vancomycin hydrochloride ... to determine bioequivalence, provided that the generic product has the same inactive ingredients (Q1) ...

Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children

... Since major pharmacy retailers are promoting generic drug programs, patients may find a more ... formulations may cost more compared to the generic medications, so it is important for patients to discuss generic options with their dermatologist," said Dr. ...

Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study

... ), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the ... is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented ... strategy on the development of first-to-market generic and innovative pharmaceuticals, and has ...

Watson Launches Generic Biaxin(R) XL

... Clarithromycin Extended-Release product is the generic equivalent to Abbott's Biaxin(R) XL, which is ... September 2007, Biaxin(R) XL and its generic equivalents had total U.S. sales of approximately ... markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth ...

Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP

... mg, and 10 mg/325 mg strengths. The Office of generic Drugs, U.S. Food and Drug Administration, has ... RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. ... producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals ...

RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days

... was developed and is manufactured by Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals. In an analysis of data pooled ... development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on ...

Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel

... New Drug Application (ANDA) for Clindamycin Phosphate Foam 1%, a generic version of Evoclin(R) Foam 1%. The Company believes that Cobrek is the ... healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ...

New, Published GELNIQUE Data Show Efficacy, Convenience and Excellent Tolerability

... hydrochloride developed and marketed by Watson (NYSE: WPI ), a leader in generic and specialty branded pharmaceuticals. Because the active ingredient in ... development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on ...

PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy

... - Ataluren designated as generic name for PTC124 - SOUTH PLAINFIELD, N.J., Feb. 3 /PRNewswire/ -- PTC ... The company also announced today that PTC124 has been issued the generic name, ataluren. (Logo: ...

Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent

... of Mutual, Mylan and Impax requesting approval to manufacture and sell generic versions of DORYX 100 and 75 mg delayed-release tablets prior to the ... industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to ...

ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study

... and advanced or metastatic breast cancer. Worldwide sales of Navelbine and generic formulations of vinorelbine in 2006 were in excess of $200 million. Navelbine and its generic equivalents are often associated with injection site reactions, including ...

Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood

... risks that may arise from the outcome of any appeal, the adverse impact of generic product distributed into the market by Apotex, the potential launch of a generic clopidogrel bisulfate product by other entities, as well as those ...

ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study

... or in combination with cisplatin. Worldwide annual sales of Navelbine and generic vinorelbine in 2006 were approximately $200 million. "Completing ... is a crossover comparison of ANX-530 and Navelbine, also available as generic vinorelbine, with a primary endpoint of pharmacokinetic equivalence of ...

Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations

... this treatment available to the rest of the world, or license it out to a generic drug manufacturer, such as Cipla, which already produces a generic version in India, that will. In the instances where the registration ...

Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms

... initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated ...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals, and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

... Inc. Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or ...

ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients

... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

... patients, 7 percent (250mg) and 10 percent (500mg) of Pentasa (R) (mesalamine) patients, 10 percent of balsalazide [combined results from generic balsalazide disodium and Colazal(R) (balsalazide disodium)] patients, and 10 percent (500mg) of Dipentum (R) (olsalazine sodium) patients were ...

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

... initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...

Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery

... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...

Jubilant Enters Research Collaboration With AstraZeneca

... (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and healthcare. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these ...

Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG

... as well as the company's value." Fluidosomes-tobramycin combines the companys proprietary Fluidosomes technology with the well-established generic drug tobramycin. Utilising synthetic liposomes containing tobramycin, a standard nebulizer delivers the drug directly to the endobronchial sites of ...

Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA

... 200,000 people. This provides Oasmia with seven year market exclusivity on the indication when the pharmaceutical is approved. There is no direct generic competition during the period and FDA often provides technical and financial assistance to expedite and optimize drug development. The ...

Strativa Pharmaceuticals Provides Product Pipeline Update

... information, please visit www.strativapharma.com . About Par Pharmaceutical Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com . ...

Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)

... Inc. Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical). In the U.S., the ...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

... Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing ...

Schering-Plough Announces Results of the Early ACS Trial

... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

... including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further ...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

... About Endo Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of ...

Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.

... CEO of Pharmacyclics noted, "We appreciate the vote of confidence by the principals of PBG, all extremely successful biotech, pharmaceutical and/or generic drug industry executives who have separately built three billion dollar plus companies. We are in active communication with the principals of PBG ...
Other Contents
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/17/2015)... SAN DIEGO , March 17, 2015 /PRNewswire/ ... and emotion analytics software, today announced general availability ... on-demand web service for the analysis of facial ... they experience advertising, media content, products and services. ... customer attention, engagement and sentiment - as derived ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
(Date:3/28/2015)... 28, 2015 Coffee could not only perk ... you from gum disease, researchers have found. , They found ... , Coffee contains antioxidants. Antioxidants fight gum disease. Does coffee, ... at Boston Univ. Henry M. Goldman School of Dental Medicine ... 2014 issue of the Journal of Periodontology. , “This is ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... March 28, 2015 India Network ... is made available to all visitors who purchase the ... All members are encouraged to purchase the insurance program ... lack of proper coverage for pre-existing medical conditions. Parents ... or two medical conditions with serious consequences to their ...
(Date:3/28/2015)... 2015 One in three young athletes ... presented today at the American Orthopaedic Society for Sports ... the long term success of surgery for patients aged ... data from 242 patients who underwent ACL reconstruction between ... MBBS, FRACS, from North Sydney Orthopaedic and Sports Medicine ...
(Date:3/28/2015)... Genomic medicine experts have sequenced the genomes ... first time, key information for understanding and treating this ... posted story on the Surviving Mesothelioma website. ... the British Columbia Cancer Agency, and PhenoPath lab in ... alterations and mutations that can lead to peritoneal ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
Other TagsOther Tags